EN 
FR 
Empowering Healthcare Decisions with Health Economics and Outcomes Research
Work with our industry-leading experts to establish the evidence you need to launch new products, navigate regulatory complexities, and achieve payer approval.
Comprehensive HEOR Services
Establishing a credible evidence base is essential to validate and document the economic value of novel products and therapeutic approaches. Cytel is a global leader in Health Economics & Outcomes Research, with a multidisciplinary team recognized for pioneering innovative methods shaping the industry. We offer tailored solutions to pharmaceutical, biotech, and medical device companies across the product lifecycle.
Our HEOR experts guide your healthcare decision-makers through treatment costs and benefits with innovative scientific methods. We understand local and global HEOR evidence needs and offer industry-leading expertise in advanced analytics, robust methods, and strategic research innovation. Leveraging our extensive experience in harnessing data from diverse international markets, we balance scientific rigor with commercial insight to provide the evidence you need to achieve the best possible health outcomes.
Contact usGlobal expertise
Recognized worldwide, our team offers localized insights across diverse healthcare systems.
Advanced analytical methods
We employ the latest in health economics methodologies to ensure precision and reliability.
Strategic innovation
We lead with pioneering research and HEOR strategies that transform healthcare decision-making.
Tailored solutions
We offer customized HEOR services that align with your specific product needs and market demands.
HEOR Expertise and Thought Leadership
Cytel’s HEOR services are comprehensive and designed to support all phases of healthcare product development and market introduction:
- Evidence review and synthesis: Ensure robust and credible evidence to support your product’s value. We are committed to the high-evidentiary standards established by Health Technology Agencies (HTAs) worldwide. Our team includes researchers with training across the spheres of health and medical sciences.
- Data science and analytics: Enhance decision-making with precise and insightful data analytical methods. Our cutting-edge predictive and database analytical methods inform your economic modeling and decision-making.
- Health economic modeling: Optimize your market access strategy with proven economic models. We are industry-recognized for our cutting-edge modeling approaches, including budget impact, cost-effectiveness, and cost-offset models, designed for successful HTA submissions globally.
- HTA trial analyses: Improve the chances of favorable HTA reviews and reimbursements with expert trial analyses. Cytel excels in trial data analysis, informing models, treatment comparisons, value communication, and reimbursement submissions, demonstrating leadership in data analytics and trial interpretation.
- Value and access: Strengthen your market access and value demonstration from the early stages. Cytel’s early value framework includes thorough evidence review and economic modeling, along with expert support in patient-reported outcomes strategy, HTA submissions, and affiliate training.
- Value communication: Effectively convey your product’s value to stakeholders and decision-makers. Our value communication consultants provide a comprehensive range of HEOR and market access communication services, including product value propositions, global value dossiers, Academy of Managed Care Pharmacy dossiers, HTA submissions, early scientific advice briefing books, infographics, white papers, and HEOR publication support.
Advanced Modeling for Informed Healthcare Decisions
Cytel excels in health economic modeling, providing foundational tools for strategic decision-making in healthcare. Our models are meticulously crafted to meet local and international standards, supporting your HTA submissions and payer negotiations globally. We specialize in:
- Cost-Effectiveness Analysis (CEA)
- Cost-Utility Analysis (CUA)
- Budget Impact Models (BIM)
- Disease Progression and Outcome Simulations
These models are developed using rigorous methodologies, including decision-tree analyses, Markov models, and dynamic simulations, to ensure you can demonstrate the economic and clinical value of your innovations effectively and convincingly.
>1,000
HEOR publications in JAMA, Lancet, and the BMJ
>90
Experts in our multidisciplinary team
8
Our Health Economics presence spans 8 countries across 4 continents
Webinar HEOR
Watch our webinar on US Drug Pricing Reform: Potential impact on Pharma HEOR evidence generation.
Watch Webinar
Claim your free 30-minute strategy session
Book a free, no-obligation strategy session with a Cytel expert to get advice on how to improve your drug's probability of success and plot a clearer route to market.